Olysio cleared in Europe


The European Commission approves J&J (JNJ) unit Janssen Pharmaceuticals' Olysio (simeprivir) for the treatment of Hepatitis C genotype 1 and 4 infection in combination with other medicines.

Olysio is already approved for sale in the U.S., Japan, Canada and Russia. It will be available in the EU in 2H 2014.

Related tickers: (GILD) (ABBV) (BMY) (MRK)

From other sites
Comments (3)
  • wam350
    , contributor
    Comments (170) | Send Message
     
    More good news.
    16 May 2014, 09:50 AM Reply Like
  • Salty32
    , contributor
    Comment (1) | Send Message
     
    What impact does this have on the demand for Gilead's Hep C drug?
    16 May 2014, 12:39 PM Reply Like
  • User 25598103
    , contributor
    Comment (1) | Send Message
     
    Fine, if the price is acceptable.
    16 May 2014, 02:42 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs